| 前收盘价格 | 44.95 |
| 收盘价格 | 44.66 |
| 成交量 | 452,062 |
| 平均成交量 (3个月) | 508,980 |
| 市值 | 1,208,433,536 |
| 价格/销量 (P/S) | 7.93 |
| 股市价格/股市净资产 (P/B) | 114.73 |
| 52周波幅 | |
| 利润日期 | 4 Nov 2025 |
| 营业毛利率 | -125.70% |
| 营业利益率 (TTM) | -99.16% |
| 稀释每股收益 (EPS TTM) | -4.76 |
| 季度收入增长率 (YOY) | 286.80% |
| 总债务/股东权益 (D/E MRQ) | 1,016.89% |
| 流动比率 (MRQ) | 8.25 |
| 营业现金流 (OCF TTM) | -108.78 M |
| 杠杆自由现金流 (LFCF TTM) | -60.04 M |
| 资产报酬率 (ROA TTM) | -15.14% |
| 股东权益报酬率 (ROE TTM) | -343.83% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | AnaptysBio, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 1.5 |
| 内部交易活动 | -3.5 |
| 价格波动 | -0.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.5 |
| 平均 | -0.40 |
|
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 5.09% |
| 机构持股比例 | 133.99% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 100.00 (Guggenheim, 131.48%) | 购买 |
| 中 | 55.50 (28.47%) | |
| 低 | 36.00 (Truist Securities, -16.67%) | 保留 |
| 平均值 | 62.38 (44.40%) | |
| 总计 | 7 购买, 1 保留 | |
| 平均价格@调整类型 | 40.82 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| UBS | 07 Jan 2026 | 70.00 (62.04%) | 购买 | 45.21 |
| Barclays | 17 Dec 2025 | 55.00 (27.31%) | 购买 | 45.69 |
| 11 Nov 2025 | 70.00 (62.04%) | 购买 | 33.56 | |
| Stifel | 11 Dec 2025 | 56.00 (29.63%) | 购买 | 45.78 |
| 29 Oct 2025 | 80.00 (85.19%) | 购买 | 36.12 | |
| HC Wainwright & Co. | 24 Nov 2025 | 51.00 (18.06%) | 购买 | 41.95 |
| 11 Nov 2025 | 52.00 (20.37%) | 购买 | 33.56 | |
| Wedbush | 24 Nov 2025 | 50.00 (15.74%) | 购买 | 41.95 |
| Truist Securities | 10 Nov 2025 | 36.00 (-16.67%) | 保留 | 33.98 |
| Guggenheim | 05 Nov 2025 | 100.00 (131.48%) | 购买 | 36.00 |
| Wells Fargo | 05 Nov 2025 | 81.00 (87.50%) | 购买 | 36.00 |
| 显示更多 | ||||
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| FAGA DANIEL | - | 44.07 | -38,792 | -1,702,879 |
| LIZZUL PAUL F. | - | 44.07 | -10,104 | -443,175 |
| LOUMEAU ERIC J | - | 44.36 | -14,832 | -661,443 |
| MARQUET MAGDA | - | 46.31 | -11,000 | -509,410 |
| MULROY DENNIS | - | 44.07 | -7,786 | -341,699 |
| 累积净数量 | -82,514 | |||
| 累积净值 ($) | -3,658,606 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 44.31 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| MARQUET MAGDA | 董事 | 15 Jan 2026 | 卖 (-) | 11,000 | 46.31 | 509,410 |
| MARQUET MAGDA | 董事 | 15 Jan 2026 | 执行期权 | 11,000 | - | - |
| FAGA DANIEL | 职员 | 08 Jan 2026 | 卖 (-) | 14,281 | 43.80 | 625,508 |
| LOUMEAU ERIC J | 职员 | 08 Jan 2026 | 卖 (-) | 2,210 | 43.80 | 96,798 |
| MULROY DENNIS | 职员 | 08 Jan 2026 | 卖 (-) | 2,515 | 43.80 | 110,157 |
| LIZZUL PAUL F. | 职员 | 08 Jan 2026 | 卖 (-) | 3,650 | 43.80 | 159,870 |
| MULROY DENNIS | 职员 | 07 Jan 2026 | 卖 (-) | 1,908 | 45.21 | 86,261 |
| FAGA DANIEL | 职员 | 07 Jan 2026 | 卖 (-) | 9,202 | 45.21 | 416,022 |
| LIZZUL PAUL F. | 职员 | 07 Jan 2026 | 卖 (-) | 2,235 | 45.21 | 101,044 |
| LOUMEAU ERIC J | 职员 | 07 Jan 2026 | 卖 (-) | 2,017 | 45.21 | 91,189 |
| LOUMEAU ERIC J | 职员 | 07 Jan 2026 | 自动卖出 (-) | 7,622 | 45.21 | 344,591 |
| FAGA DANIEL | 职员 | 07 Jan 2026 | 执行期权 | 26,838 | - | - |
| LOUMEAU ERIC J | 职员 | 07 Jan 2026 | 执行期权 | 5,888 | - | - |
| MULROY DENNIS | 职员 | 07 Jan 2026 | 执行期权 | 6,700 | - | - |
| LIZZUL PAUL F. | 职员 | 07 Jan 2026 | 执行期权 | 8,525 | - | - |
| MULROY DENNIS | 职员 | 06 Jan 2026 | 执行期权 | 5,245 | - | - |
| FAGA DANIEL | 职员 | 06 Jan 2026 | 执行期权 | 17,850 | - | - |
| LIZZUL PAUL F. | 职员 | 06 Jan 2026 | 执行期权 | 6,145 | - | - |
| LOUMEAU ERIC J | 职员 | 06 Jan 2026 | 执行期权 | 5,545 | - | - |
| LOUMEAU ERIC J | 职员 | 05 Jan 2026 | 卖 (-) | 2,983 | 43.20 | 128,866 |
| LIZZUL PAUL F. | 职员 | 05 Jan 2026 | 卖 (-) | 4,219 | 43.20 | 182,261 |
| MULROY DENNIS | 职员 | 05 Jan 2026 | 卖 (-) | 3,363 | 43.20 | 145,282 |
| FAGA DANIEL | 职员 | 05 Jan 2026 | 卖 (-) | 15,309 | 43.20 | 661,349 |
| 显示更多 | ||||||
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合